Instituut voor Neuropathische Pijn

Home

English articles

Research & Development

AstraZeneca and neuropathic pain

AstraZeneca, a pharmaceutical company, has three compounds in clinical development for neuropathic pain:

AZD2423 chemokine antagonist in chronic neuropathic pain in phase I
AZD2066 metabotropic glutamate receptor antagonist for chronic neuropathic pain in phase II
AZD2516 metabotropic glutamate receptor 5 in chronic neuropathic pain in phase I

The antagonizing effects of the gutamate receptor could have pain relieving effects.^[1] Allodynia was partially reversed in an animal model.^[2] Also secondary hyperalgesia can be effectively attenuated during both the development and maintenance phases of acute knee joint inflammation by spinal application. ^[3]

August 2010, Jan M. Keppel Hesselink, MD, PhD and David Kopsky, MD

Referenties

[1]: Jesse CR, Savegnago L, Nogueira CW. | Effect of a metabotropic glutamate receptor 5 antagonist, MPEP, on the nociceptive response induced by intrathecal injection of excitatory aminoacids, substance P, bradykinin or cytokines in mice. | Pharmacol Biochem Behav. | 2008 Oct;90(4):608-13.

[2]: Dogrul A, Ossipov MH, Lai J, Malan TP Jr, Porreca F. | Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGLUR(5)) antagonist, in experimental neuropathic pain in rats. | Neurosci Lett. | 2000 Oct 6;292(2):115-8.

[3]: Zhang L, Lu Y, Chen Y, Westlund KN. | Group I metabotropic glutamate receptor antagonists block secondary thermal hyperalgesia in rats with knee joint inflammation. | J Pharmacol Exp Ther. | 2002 Jan;300(1):149-56.